Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Phase 2

Recruiting

• Conditions: HER2 Negative; Low PD-L1 Expressing; Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
• Interventions: Drug: Iparomlimab and Tuvonralimab (QL1706); Drug: Oxallplation; Drug: Capectitabine Tablets

• Registration Number: NCT06932068
• Lead Sponsor: Qilu Hospital of Shandong University

Brief Summary

This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma

Detailed Description

Not available

Study Timeline

• Study Start: 2025-03-26
• Status Verified: 2025-04
• Study First Submitted: 2025-04-10
• Study First Submitted QC: 2025-04-16
• Last Update Submitted: 2025-04-16
• Study First Posted: 2025-04-17
• Last Update Posted: 2025-04-17
• Primary Completion: 2026-10-31
• Study Completion: 2027-10-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 77

Inclusion Criteria

1. Aged 18-75 years, gender is not limited;
2. Pathologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma that is inoperable or has distant metastasis;
3. HER2-negative by immunohistochemistry (IHC);
4. low PD-L1 expression status (CPS < 5);
5. Has at least 1 measurable lesion as determined by RECIST 1.1;
6. No systematic treatment in the past, or the patient has received neoadjuvant/adjuvant chemotherapy, but the disease progresses or relapses more than 6 months after the end of treatment;
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
8. Adequate organ function;
9. The life expectancy is at least 3 months;
10. Willing to join the study and signed an informed consent form (ICF) with good compliance and cooperation in follow-up.

Exclusion Criteria

1. Allergic to any trial drug and its excipients, or serious allergy history, or contraindication of the trial drug;
2. Cardiovascular and cerebrovascular events that are not well controlled;
3. Has received systematic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use for ascites control) before the first administration within 2 weeks;
4. Have a history of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, or systemic disease with poor control (including but not limited to diabetes, hypertension, etc.);
5. Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases;
6. Severe chronic or active infection requires systemic antibacterial, antifungal or antiviral treatment, including tuberculosis infection.Have a history of active tuberculosis infection ≥ 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment;
7. Brain metastasis or leptomeningeal metastasis;
8. Clinically significant pleural effusion, pericardial effusion or ascites should be drained for many times within 2 weeks before the first administration of the trial drug;
9. Has a second clinically detectable primary malignant tumor at the time of recruitment, or there were other malignant tumors in the past 5 years (except for fully treated skin basal cell carcinoma or cervical carcinoma in situ);
10. Any major surgery was performed ≤ 28 days before the first trial drug administration;
11. History of allogeneic stem cell transplantation or organ transplantation;
12. Duodenal ulcer, ulcerative colitis, intestinal obstruction and other gastrointestinal diseases at present; or other conditions that may cause gastrointestinal bleeding or perforation judged by the researchers; or history of intestinal perforation or fistula, but has not recovered after surgical treatment;
13. Live vaccine was inoculated within 4 weeks (inclusive) before the first administration of the trial drug, not including seasonal influenza vaccines but intranasal vaccine.
14. Has other factors that may lead to the forced termination of this trial according to the judgment of the investigator, such as other serious diseases (including psychological and mental diseases) requiring combined treatment, serious laboratory examination abnormalities, and family or social factors, which may affect the safety of the subject, or the collection of data and samples;
15. Participating in other therapeutic clinical studies or using research instruments within 4 weeks before the first administration;
16. Others conditions do not meet the inclusion according to the judgment of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
QL1706 + XELOX chemotherapy	Oxallplation	Iparomlimab and Tuvonralimab+XELOX
QL1706 + XELOX chemotherapy	Iparomlimab and Tuvonralimab (QL1706)	Iparomlimab and Tuvonralimab+XELOX
QL1706 + XELOX chemotherapy	Capectitabine Tablets	Iparomlimab and Tuvonralimab+XELOX

Primary Outcome Measures

Name	Time	Method
progression-free survival (PFS)	12 months after the last subject participating in	The time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first (per RECIST 1.1).

Secondary Outcome Measures

Name	Time	Method
overall survival (OS)	12 months after the last subject participating in	The time from the starting date of study drug to the date of death due to any cause.
objective response rate (ORR)	6 months after the last subject participating in	The proportion of subjects with complete response (CR) and partial response (PR) according RESIST1.1 in total subjects.
Safety (adverse event)	Up to approximately 2 years	The rates of adverse events.
duration of response (DOR)	12 months after the last subject participating in	The time from the date for first documented response of complete response (CR) or partial response (PR) to the date of first documented of disease progression or death, whichever occurs first.
disease control rate (DCR)	12 months after the last subject participating in	The proportion of subjects with complete response (CR) and partial response (PR) and stable disease(SD) in total subjects

Trial Locations

Locations (1)

Qilu Hospital of Shandong University; 🇨🇳 Jinan, Shandong, China